ibj.com
Cure8 news brief
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
Medications
Mirikizumab
IL-23 inhibitor
Abdominal Pain
Rectal Bleeding
Urgency
Regulatory Update
Adult patients
Why This Matters
A newly approved biologic, Omvoh (mirikizumab), gives another FDA‑approved treatment option for adults with moderate to severe Crohn’s disease and adds to Lilly’s role in IBD care.
The article highlights trial results, company acquisitions, and access/coverage topics that could affect treatment choices and availability.
Who Should Pay Attention
Adults with Crohn’s or ulcerative colitis; patients on or considering biologics; IBD clinicians; researchers and people tracking drug access and cost.
Study Snapshot
Story typeMainstream News
Evidence typeRegulatory update
Source depthFull source text
What To Know
Omvoh is a biologic that targets interleukin-23 p19 (IL‑23p19) and the FDA approval cited Phase 3 results showing higher rates of clinical remission and intestinal healing versus placebo at one year. Lilly is pursuing additional IBD approaches, including an oral α4β7-targeting program from Morphic and has submitted or plans submissions outside the U.S.
Coverage by major pharmacy benefit managers and employer cost data are also mentioned. The article is a company- and business-focused report rather than a clinical guideline. It summarizes regulatory and trial outcomes reported by Lilly and public sources; it does not provide treatment recommendations or detailed safety information.
Keep In Mind
The report summarizes regulatory approval, company strategy, and headline Phase 3 outcomes but is not a clinical trial publication. Early‑stage research mentioned (oral α4β7 programs) is still in Phase 2. Coverage and cost details are summarized at a high level; check insurer policies and prescribing information for specifics.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationibj.com
Indexed viaBing News
Source typeMainstream News
PublishedJan 29, 2025, 5:43 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly secures FDA approval for Omvoh to treat Crohn's disease
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.
Eli Lilly's Omvoh granted FDA approval to treat Crohn's disease in adults - PMLiVE
A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...